These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 25919147)

  • 21. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
    Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
    Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
    Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIF-1α and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma.
    Kwon OJ; Park JJ; Ko GH; Seo JH; Jeong BK; Kang KM; Woo SH; Kim JP; Hwa JS; Carey TE
    Head Neck; 2015 Apr; 37(4):505-10. PubMed ID: 24677746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.
    Overgaard J
    Radiother Oncol; 2011 Jul; 100(1):22-32. PubMed ID: 21511351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma.
    Tawk B; Schwager C; Deffaa O; Dyckhoff G; Warta R; Linge A; Krause M; Weichert W; Baumann M; Herold-Mende C; Debus J; Abdollahi A
    Radiother Oncol; 2016 Feb; 118(2):350-8. PubMed ID: 26711490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer.
    Winter SC; Shah KA; Han C; Campo L; Turley H; Leek R; Corbridge RJ; Cox GJ; Harris AL
    Cancer; 2006 Aug; 107(4):757-66. PubMed ID: 16826581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.
    Téllez-Gabriel M; Arroyo-Solera I; León X; Gallardo A; López M; Céspedes MV; Casanova I; López-Pousa A; Quer M; Mangues MA; Barnadas A; Mangues R; Pavón MA
    Cancer Med; 2013 Dec; 2(6):950-63. PubMed ID: 24403269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial.
    Nijkamp MM; Span PN; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende PL; de Jong M; van der Kogel AJ; Bussink J; Kaanders JH
    Eur J Cancer; 2013 Oct; 49(15):3202-9. PubMed ID: 23867129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation.
    van den Broek GB; Wildeman M; Rasch CR; Armstrong N; Schuuring E; Begg AC; Looijenga LH; Scheper R; van der Wal JE; Menkema L; van Diest PJ; Balm AJ; van Velthuysen ML; van den Brekel MW
    Int J Cancer; 2009 Jun; 124(11):2643-50. PubMed ID: 19253368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microsatellite alterations in head and neck squamous cell carcinoma and relation to expression of pimonidazole, CA IX and GLUT-1.
    De Schutter H; Barbé B; Spaepen M; Begg AC; Balm A; Gregoire V; Haustermans K; Mahy P; Vander Poorten V; Nuyts S
    Radiother Oncol; 2006 Aug; 80(2):143-50. PubMed ID: 16916559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease.
    Krstevska V
    J BUON; 2015; 20(4):943-53. PubMed ID: 26416042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxic regulation of the PERK/ATF4/LAMP3-arm of the unfolded protein response in head and neck squamous cell carcinoma.
    Nagelkerke A; Sweep FC; Stegeman H; Grénman R; Kaanders JH; Bussink J; Span PN
    Head Neck; 2015 Jun; 37(6):896-905. PubMed ID: 24634103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. microRNAs are important players in head and neck carcinoma: a review.
    Janiszewska J; Szaumkessel M; Szyfter K
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):716-28. PubMed ID: 23948550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of activin receptor-like kinase 1 among patients with head and neck cancer.
    Chien CY; Chuang HC; Chen CH; Fang FM; Chen WC; Huang CC; Huang HY
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):965-73. PubMed ID: 23447486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma.
    Patel MR; Zhao N; Ang MK; Stadler ME; Fritchie K; Weissler MC; Zanation AM; Harris SL; Funkhouser WK; Olshan AF; Shores CG; Hayes DN
    Otolaryngol Head Neck Surg; 2013 Oct; 149(4):587-95. PubMed ID: 23846458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoxia promotes migration/invasion and glycolysis in head and neck squamous cell carcinoma via an HIF-1α-MTDH loop.
    Zhu G; Peng F; Gong W; She L; Wei M; Tan H; Chen C; Zhang D; Li G; Huang D; Zhang X; Liu Y
    Oncol Rep; 2017 Nov; 38(5):2893-2900. PubMed ID: 28901527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.